Pain pumps deliver continuous local anesthetic into a joint after surgery. After clinical reports linked these catheters to glenohumeral chondrolysis, this study built a rabbit model to test whether continuous intra-articular bupivacaine is actually toxic to cartilage. Thirty rabbits received a 48-hour glenohumeral infusion of saline, bupivacaine, or bupivacaine with epinephrine.
When a young patient presents with rapid-onset glenohumeral arthritis after an otherwise routine arthroscopic shoulder procedure, ask what was in the joint afterward. This paper gave experimental backing to the clinical reports that a continuous intra-articular bupivacaine pain pump can destroy cartilage.
The key mental model: a single injection is tolerated, but 48 hours of continuous exposure in a small, low-volume joint is a different insult entirely. The shoulder cannot dilute the drug the way the knee can. Epinephrine is not protective. The toxicity is the bupivacaine.
This is an animal model, so it shows the mechanism, not the human incidence. But combined with the case reports, it was enough to move practice away from intra-articular pain catheters in the shoulder. For boards: link pain pump plus glenohumeral joint plus young patient plus rapid chondrolysis.
Pain pumps deliver continuous local anesthetic into a joint after surgery. After clinical reports linked these catheters to glenohumeral chondrolysis, this study built a rabbit model to test whether continuous intra-articular bupivacaine is actually toxic to cartilage. Thirty rabbits received a 48-hour glenohumeral infusion of saline, bupivacaine, or bupivacaine with epinephrine.
When a young patient presents with rapid-onset glenohumeral arthritis after an otherwise routine arthroscopic shoulder procedure, ask what was in the joint afterward. This paper gave experimental backing to the clinical reports that a continuous intra-articular bupivacaine pain pump can destroy cartilage.
The key mental model: a single injection is tolerated, but 48 hours of continuous exposure in a small, low-volume joint is a different insult entirely. The shoulder cannot dilute the drug the way the knee can. Epinephrine is not protective. The toxicity is the bupivacaine.
This is an animal model, so it shows the mechanism, not the human incidence. But combined with the case reports, it was enough to move practice away from intra-articular pain catheters in the shoulder. For boards: link pain pump plus glenohumeral joint plus young patient plus rapid chondrolysis.